Ralliant (NYSE:RAL) Stock Rating Lowered by Vertical Research

by · The Cerbat Gem

Ralliant (NYSE:RAL – Get Free Report) was downgraded by stock analysts at Vertical Research from a “buy” rating to a “hold” rating in a report issued on Wednesday, Marketbeat.com reports. They currently have a $65.00 target price on the stock. Vertical Research’s target price suggests a potential upside of 4.77% from the company’s previous close.

RAL has been the subject of a number of other reports. Wall Street Zen upgraded Ralliant from a “hold” rating to a “buy” rating in a research report on Saturday. Citigroup raised their price objective on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. TD Cowen raised their price objective on Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday, May 20th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Finally, Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research note on Monday, April 13th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $64.50.

View Our Latest Analysis on Ralliant

Ralliant Price Performance

Shares of RAL opened at $62.04 on Wednesday. Ralliant has a 1 year low of $37.27 and a 1 year high of $62.95. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The company has a market capitalization of $6.94 billion and a price-to-earnings ratio of -5.67. The business has a 50-day moving average of $47.64 and a 200-day moving average of $48.37.

Ralliant (NYSE:RAL – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million during the quarter. The business’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities research analysts anticipate that Ralliant will post 2.64 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Karen M. Bick sold 2,530 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $46.50, for a total transaction of $117,645.00. Following the completion of the sale, the senior vice president owned 42,652 shares of the company’s stock, valued at $1,983,318. This trade represents a 5.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Institutional Investors Weigh In On Ralliant

Large investors have recently added to or reduced their stakes in the business. Irenic Capital Management LP grew its stake in Ralliant by 424.1% in the first quarter. Irenic Capital Management LP now owns 1,740,218 shares of the company’s stock valued at $72,376,000 after acquiring an additional 1,408,176 shares during the period. Amundi grew its stake in Ralliant by 6.2% in the first quarter. Amundi now owns 148,614 shares of the company’s stock valued at $6,181,000 after acquiring an additional 8,649 shares during the period. California State Teachers Retirement System grew its stake in Ralliant by 23.1% in the first quarter. California State Teachers Retirement System now owns 130,822 shares of the company’s stock valued at $5,441,000 after acquiring an additional 24,591 shares during the period. Royal Bank of Canada grew its stake in Ralliant by 175.7% in the first quarter. Royal Bank of Canada now owns 50,251 shares of the company’s stock valued at $2,091,000 after acquiring an additional 32,024 shares during the period. Finally, Rokos Capital Management LLP acquired a new stake in Ralliant in the first quarter valued at approximately $42,022,000.

About Ralliant

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Further Reading